OncUpdates· @OncUpdates · X·· 14 小时前评分70
正文 · 原文
⭐️ #ESMO26 #LCSM
🔥 DeLLphi-305: Tarla + Durva vs Durva as 1L maintenance after chemo-IO in ES-SCLC
🎯 mOS 21.1 vs 12.7 mo
✅ mPFS 7.4 vs 1.9 mo
✅ ORR 26.4% vs 4.1%
⚠️ CRS 49.6%
🔑New SOC for maintenance therapy in ES-SCLC
#OncTwitter #SCLC @myESMO @sands_jacob #LungCancer
81 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：OncUpdates · x.com